IJTLD OPEN editorial
The TB drug development pipeline currently includes more novel compounds in phase 2 trials than ever before. A new editorial, published in IJTLD OPEN, underscores the ethical and public health imperative of ensuring access to these promising agents through systematic compassionate use programmes. The piece argues that expanding such access should be an urgent priority for all TB stakeholders.
“We urge NCEDs [novel chemical entity developers] and other stakeholders to examine current delays in CU [compassionate use], re-evaluate any false precepts, and draw on the experiences of existing frameworks to strengthen work with stakeholders to ensure a human rights–based approach to CU access. CU programmes are… a moral and ethical imperative, especially for diseases that have a public health risk. By providing treatment for otherwise incurable forms of TB, we can ensure scientific progress benefits not just a few individuals in trials but entire communities, upholding the right to health and scientific progress for all.”
Read the full editorial here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #3, 25 January 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : IJTLD OPEN
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.